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ABSTRACT
Patients with tumor-induced osteomalacia (TIO), an acquired paraneoplastic condition characterized by osteomalacia due to hypo-
phosphatemia, exhibit a similar clinical picture to those with X-linked hypophosphatemic rickets/osteomalacia (XLH). The human
monoclonal anti-fibroblast growth factor 23 (FGF23) antibody burosumab (KRN23) increases serum phosphate and improves bone
turnover, fracture healing, pain, and physical function in XLH patients by inhibiting circulating FGF23; thus, burosumab is expected
to be an effective treatment for TIO. We report here an interim analysis of a multicenter, open-label, intraindividual dose-adjustment
study of burosumab (0.3 to 2.0 mg/kg every 4 weeks) in Japanese and Korean TIO patients. The primary endpoint was the fasting
serum phosphate level at each visit. Key secondary endpoints were changes over time in bone biomarkers, pharmacodynamic
markers, bone histomorphometric parameters, motor function, and patient-reported outcomes. Safety was assessed based on
treatment-emergent adverse events (TEAEs). Thirteen patients received burosumab treatment, of whom 4 underwent bone biopsy.
Themean dose after week 112was approximately 1.0 mg/kg. After the first burosumab administration, mean serum phosphate levels
increased and remained above the lower limit of normal and in the normal range from weeks 14 to 112. Bone biomarkers initially
increased, reachingmaximum values at week 16 or 24, and then gradually decreased. After burosumab treatment, patients were able
to walk further (evaluated by the 6-minute walk test), reported decreased pain levels, and showed a tendency toward healing of base-
line fractures and pseudofractures. Two patients discontinued, one each due to disease progression and consent withdrawal. Buro-
sumabwas generally well tolerated, with no treatment-related TEAEs of grade ≥3 and no treatment-related serious AEs. In conclusion,
the interim results of this first study of burosumab to treat TIO patients indicate that this drug has the potential to provide clinical
benefit for patients with unresectable tumors. The full study results are eagerly anticipated. © 2020 The Authors. Journal of Bone
and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)..
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Introduction
Tumor-induced osteomalacia (TIO) is a rare form of fibroblastgrowth factor 23 (FGF23)-related hypophosphatemic dis-
ease, in which overproduction of FGF23 leads to renal phosphate
wasting and a reduction in intestinal phosphate absorption due
to inappropriately suppressed 1,25-dihydroxyvitamin D (1,25
(OH)2D) levels, followed by hypophosphatemia.
(1–4) Patients with
TIO present similar clinical and biochemical features as those
with other FGF23-related hypophosphatemic diseases, such as
X-linked hypophosphatemic rickets/osteomalacia (XLH).(5,6) Clin-
ical features of TIO generally include bone pain, muscle weak-
ness, and progressive fatigue, and patients often present with
fractures of the long bones, vertebrae, and ribs.(4,7) Bone histo-
logic analysis and quantitative backscattered electron imaging
analysis reveal marked alterations in mineralization kinetics, as
evidenced by a reduced degree of mineralization and increased
osteoid abundance.(8,9)
Unlike the genetic disease XLH, TIO is an acquired paraneo-
plastic condition in which the tumor produces excessive levels
of FGF23,(2,4,7) and the time between onset of symptoms to diag-
nosis can be lengthy, taking up to 20 years.(10) The causative
tumors in TIO are typically benign, characterized by small size
and slow growth and can occur at various sites;(11) they may be
difficult to identify and diagnose with standard imaging tech-
niques.(7,11) For tumor lesions that can be identified and are
accessible, surgical complete resection is the first treatment
choice.(2,4) After complete resection, blood FGF23 levels
decrease markedly and immediately, and biochemical parame-
ters commonly resolve within days or weeks.(12) If the tumor can-
not be identified or resected, patients are treated with oral
inorganic phosphate and/or active vitamin D preparations.(4,7)
However, the efficacy of these treatments can be suboptimal,
and there are safety concerns associated with them, including
renal insufficiency and secondary hyperparathyroidism.(4,7)
Burosumab (KRN23) is a fully humanmonoclonal antibody tar-
geted against FGF23.(13) Burosumab has shown efficacy in the
treatment of XLH patients, increasing serum phosphate(14) and
improving bone histomorphometric measures and fracture heal-
ing.(15,16) Moreover, 24 weeks of burosumab treatment was asso-
ciated with improvements in pain, physical function, and
stiffness compared with placebo-treated patients with XLH.(15)
Burosumab was approved in the United States, Canada, and
the European Union for the treatment of XLH in 2018(13,17,18)
and in Japan for FGF23-related hypophosphatemic rickets and
osteomalacia in 2019.(19)
Burosumab is expected to be an effective treatment for TIO,
particularly in patients whose causative tumors are difficult to
resect surgically. Although a phase 2 clinical study
(NCT02304367) in patients with TIO is ongoing in the United
States,(20) and a single case that suggests burosumab could
improve pain and mobility was reported,(21) little is known about
the effect of burosumab on patients with TIO. We conducted a
phase 2 open-label trial, which is the first clinical study in TIO




This is an ongoing, multicenter, open-label, intraindividual dose
adjustment study, which started in May 2016 and is planned to
continue until September 2020 (Fig. 1); this report contains
interim analysis data from week 112. After obtaining informed
consent, potential participants underwent screening for eligibil-
ity. For eligible patients, a baseline examination was conducted,
with or without bone biopsy of the ileum. Burosumab treatment
was initiated 1 to 3 days after the baseline examination.
This study was an unblinded, single-arm study. It was con-
ducted in accordance with the principles described in the Decla-
ration of Helsinki, all applicable local and national laws, and
current Good Clinical Practice guidelines for Japan and the
Republic of Korea. The protocol and all study documentation
were reviewed and approved by the Institutional Review Board
or Independent Ethics Committee at each investigative site
(University of Tokyo Hospital, Toranomon Hospital, Osaka City
University Hospital, Kobe University Hospital, Severance Hospi-
tal, and Seoul National University Hospital). All patients (and their
legal representative, if patients were aged <20 years) provided
written informed consent before the conduct of any study proce-
dures. This study was registered at www.ClinicalTrials.gov under
the identifier number NCT02722798.
Patients
Key inclusion criteria were age ≥18 years; a diagnosis of TIO (ele-
vated FGF23) with unidentified or unresectable tumor; at screen-
ing, a serum phosphate level <2.5 mg/dL (the lower limit of the
normal range [LLN]), serum FGF23 level ≥100 pg/mL by Kainos
assay, and renal tubular maximum reabsorption of phosphate
(TmP)/glomerular filtration rate (GFR) <2.5 mg/dL; an estimated
GFR (eGFR; calculated using the 3-variable Japanese equation(22))
at screening ≥60 mL/min/1.73 m2, or ≥30 and <60 mL/
min/1.73 m2 with no evidence of renal failure related to nephro-
calcinosis; and a corrected serum calcium level at screening
<10.8 mg/dL. Patients with epidermal nevus syndrome (ENS),
another FGF23-associated phosphate wasting disorder,(23) were
also eligible for study participation; however, no patients with
ENS were enrolled.
Key exclusion criteria were use of TIO treatment (pharmaco-
logic vitamin D metabolites or analogs, oral phosphate, alumi-
num hydroxide antacids, acetazolamide, or thiazide diuretics)
within 14 days before screening; use of medication to suppress
parathyroid hormone (eg, cinacalcet hydrochloride) within
60 days before screening; use of therapeutic monoclonal anti-
bodies or any investigational product within 90 days before
screening; pregnancy, lactation, or unwillingness to use appro-
priate contraception; or any medical condition that could con-
found the study results or endanger the participant, or anyone
considered unsuitable for participation by the investigator.
Study treatments
Burosumab was administered subcutaneously once every
4 weeks at an initial dose of 0.3 mg/kg. The dose increment from
the preceding administration was set at 0.2 mg/kg and the max-
imum dose at 2.0 mg/kg. The dose of burosumab was adjusted
at weeks 4, 8, 12, and 16 based on the serum phosphate level
obtained 2 weeks before (ie, at weeks 2, 6, 10, and 14, respec-
tively). At and after week 20, the dose of burosumab was set at
the same level as at week 16. If there were concerns about safety
or suboptimal efficacy, the dose could be adjusted at scheduled
study visits (weeks 20, 24, 28, 32, 36, 40, 44, and at, and after,
week 48). At, and after, week 92, burosumab was administered
at a dosage based on current body weight and dose. Bone
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biopsy was performed at baseline and at week 48. In the patients
who underwent bone biopsy, tetracycline hydrochloride
(TC) was administered at weeks −3, −1, 45, and 47.
Endpoints
The primary endpoint was the serum phosphate level at each
time point. Blood was collected after a fast of ≥8 hours and
before any treatment administration; collection times are
described in the Supplemental Text (study protocol).
Secondary endpoints included the proportions of patients
who achieved mean peak and trough serum phosphate values
exceeding the LLN (2.5 mg/dL [0.81 mmol/L]); the proportion
of patients with serum phosphate values within the normal
range every 24 weeks; percentage changes from baseline in
the following bone parameters at week 48: osteoid thickness,
osteoid surface/bone surface ratio, osteoid volume/bone volume
ratio, and mineralization lag time; changes from baseline over
time in the following pharmacodynamic markers: urinary phos-
phate, serum 1,25(OH)2D, TmP/GFR, alkaline phosphatase, and
markers of calcium homeostasis (serum calcium, 24-hour urine
calcium, and intact parathyroid hormone); changes from baseline
over time in the following serummetabolic bone biomarkers: type
I collagen C-telopeptides (CTX), procollagen 1 N-terminal propep-
tide (P1NP), bone-specific alkaline phosphatase (BALP), and osteo-
calcin (OC); changes from baseline over time in motor function
(6-minute walk test [6MWT]); and changes from baseline over time
in patient-reported outcomes (brief pain inventory [BPI]). The time
points for each measurement are described in the Supplemental
Text (study protocol).
Exploratory endpoints were whole-body bone scintigraphy,
dual-energy X-ray absorptiometry scan (DXA), and standard
X-ray radiography (lateral spine, anteroposterior chest, upper
arm, lower arm, hand, bilateral upper leg, bilateral lower leg, foot,
and other). The time points for each measurement are described
in the Supplemental Text (study protocol). Fractures and pseudo-
fractures were evaluated by an independent reader.
Safety was assessed based on treatment-emergent adverse
events (TEAEs), coded using theMedical Dictionary of Regulatory
Activities (v21.0) and graded using the Common Terminology
Criteria for Adverse Events (v4.0); clinical laboratory evaluations;
renal ultrasound; and echocardiogram. Immunogenicity of
treatment, based on the development of anti-burosumab anti-
bodies, was also assessed.
Statistical methods
For the target number of patients, based on the small numbers
of TIO patients estimated in Japan(24) and the Republic of Korea
and the feasibility of the study (eg, frequency of study visits),
the present study proposed to enroll a minimum of 6 patients.
The safety analysis set comprised all patients who received a
dose of burosumab; the efficacy analysis set comprised all
patients who received a dose of burosumab and had at least 1
post-baseline serum phosphate evaluation.
For the primary endpoint, descriptive statistics of serum phos-
phate concentration at each test time point were calculated. For
the secondary endpoints, the numbers and percentages of
patients who achieved the mid-cycle and end-cycle mean serum
phosphate value exceeding the LLN were calculated; descriptive
statistics of changes and percentage changes in serum phos-
phate from baseline were also calculated. Descriptive statistics
were calculated for all other secondary outcomes. Categorical
data were summarized using frequencies and percentages; con-
tinuous data included number of patients, mean, standard devi-
ation (SD), median, minimum, and maximum. For exploratory
objectives, baseline observations and changes from baseline
over time were summarized. No statistical hypothesis testing
was performed during this study. No imputations were made
for missing data and no adjustments were made for multiplicity.
Further details of the statistical methods are included in the Sup-
plemental Text (study protocol).
Results
Patients
Regarding the patient disposition, 14 patients with TIO were
enrolled in the study; all 14 patients provided consent for treat-
ment, but only 4 provided consent for bone biopsy. One patient
withdrew consent before treatment; therefore, 13 (92.9%)
received burosumab treatment and were included in the efficacy
and safety analysis sets. At the cut-off date, 1 patient had discon-
tinued treatment because of disease progression, 1 had with-
drawn consent, and 11 (78.6%) had completed week
112 assessments.
Fig 1. Study design. aOnly in patients who gave consent for bone biopsy. TC = tetracycline hydrochloride.
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Baseline characteristics are reported in Table 1. Of the
13 patients evaluated, 9 (69.2%) were Japanese, 7 (53.8%) were
female, the mean age was 60.5 years, and the mean duration
of disease was 10.0 years. All patients (100%) had previously
used active vitamin D3, 12 (92.3%) had used inorganic phos-
phate, 2 (15.4%) each had used calcimimetics or had radiation
treatment, and 1 (7.7%) had used octreotide. Seven patients
(53.8%) had previously undergone surgery for their disease. No
patients had undergone parathyroidectomy for secondary
hyperparathyroidism. Tumors were identified in 7 (53.8%)
patients at baseline.
Themean dose of burosumab increased throughout the study
period and at week 112 was 1.05 (min 0.0, max 2.0) mg/kg.
Primary endpoint
Serum phosphate levels increased after burosumab administra-
tion (Fig. 2). The mean  SD serum phosphate level at baseline
was 1.62  0.49 mg/dL, which was below the LLN (2.5 mg/dL).
After the first administration of burosumab at a dose of 0.3 mg/
kg, mean serum phosphate levels increased and remained con-
sistently above the LLN and in the normal range from week
14 to week 112.
Secondary endpoints
Overall, 9/13 (69.2%) patients achieved mean peak serum phos-
phate levels above 2.5 mg/dL up to week 24. The mean change
in peak levels from baseline was 1.01  0.64 mg/dL
(an increase of 62.9% from baseline). Similarly, 6/13 (46.2%)
patients achieved mean trough serum phosphate levels above
2.5 mg/dL up to week 48. The mean change in trough levels
was 0.88  0.47 mg/dL (an increase of 58.2% from baseline).
The proportion of patients with serum phosphate values within
the normal range was 1/13 (7.7%) at baseline, 9/13 (69.2%) at
week 24, 8/13 (61.5%) at week 48, and 9/13 (69.2%) at weeks
72 and 96.
Bone biopsy results were determined in 3 of the 4 patients
who underwent the procedure, and the results are shown in Sup-
plemental Table S1. Data from the other patient who underwent
bone biopsy were not available because of the poor condition
of the sample. No notable change was observed in osteoid
thickness, osteoid/bone surface, and osteoid/bone volume
(Supplemental Fig. S1). Mineralization lag time cannot be mea-
sured at baseline; mean  SD value of mineralization lag time
was 393.90  487.62 at week 48.
The results of the pharmacodynamic marker analysis are sum-
marized in Fig. 3. After the start of burosumab administration,
mean  SD serum 1,25(OH)2D levels increased from baseline
(22.9  11.9 pg/mL). Changes in serum 1,25(OH)2D levels at
each time point were almost constant from week 24 onward.
Similar results were obtained for TmP/GFR, which increased from
baseline (1.15  0.43 mg/dL) and remained almost constant
from week 24 onward. Alkaline phosphatase levels increased
from baseline (424.7  184.8 U/L) to week 12 and then
decreased below the baseline value from week 48 onward.
All metabolic bone markers initially increased after the start of
burosumab administration (Supplemental Fig. S2). They reached
maximum values at week 16 or 24 and then gradually decreased.
The mean  SD value of CTX was 0.61  0.57 ng/mL at baseline;
this increased to 0.89  0.80 ng/mL at week 24, and then
decreased to 0.78  0.61 ng/mL at week 96. The mean  SD
values of P1NP at the same time points were 72.34  72.87 ng/




set N = 13
Country
Japan 9 (69.2)




Mean (SD) 60.5 (10.8)
≥65 5 (38.5)
Height (cm)
Mean (SD) 151.45 (10.43)
Weight (kg)
Mean (SD) 61.38 (13.02)
Duration of disease, years (n = 12)
Mean (SD) 10.0 (5.0)
Treatment for underlying disease
Inorganic phosphate 12 (92.3)








Tumor identified at baseline
Yes 7 (53.8)
Serum phosphatea (mg/dL)
Mean (SD) 1.62 (0.49)
Corrected serum calciumb (mg/dL)
Mean (SD) 9.02 (0.33)
1,25-dihydroxyvitamin Dc (pg/mL)
Mean (SD) 22.58 (11.87)
25-hydroxyvitamin Dd (ng/mL)
Mean (SD) 26.8 (13.2)
Parathyroid hormone,e intact (pg/mL)
Mean (SD) 112.5 (45.4)
Fibroblast growth factor 23,f intact (pg/mL)
Mean (SD) 1018.8 (1668.8)
TmP/GFR,g 2-hr urinalysis, (mg/dL)
Mean (SD) 1.1478 (0.4259)
Alkaline phosphataseh (U/L)
Mean (SD) 424.7 (184.8)
Data are shown as n (%) unless otherwise stated.
LLN = lower limit of normal; SD = standard deviation; TIO = tumor-
induced osteomalacia; TmP/GFR = renal tubular maximum phosphate
reabsorption rate/glomerular filtration rate; ULN = upper limit of normal.
aNormal range according to the central laboratory 2.4–4.3 mg/dL (the
value at baseline was below the LLN in 12/13 patients [92.3%]).
bNormal range according to the central laboratory 8.5–10.2 mg/dL (the
value at baseline was below the LLN in 1/13 patients [7.7%]).
cNormal range according to the central laboratory 20–60 pg/mL (the
value at baseline was below the LLN in 7/13 patients [53.8%]).
dNormal range according to Fukumoto et al.(27) ≥20 ng/mL (the value at
baseline was below the LLN in 3/13 patients [23.1%]).
eNormal range according to the central laboratory 10–65 pg/mL (the
value at baseline was above the ULN in 11/13 patients [84.6%]).
fNormal range according to Fukumoto et al.(27) ≥30 pg/mL (the value at
baseline was above the ULN in 13/13 patients [100%]).
gNormal ranges according to Chong et al.(7) are age- and sex-dependent
(the value at baseline was below the LLN in 13/13 patients [100%]).
hNormal range according to the central laboratory 115–359 U/L (the
value at baseline was above the ULN in 6/13 patients [46.2%]).
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mL, 112.89  105.43 ng/mL, and 91.77  78.05 ng/mL, respec-
tively. The mean  SD values of BALP were 36.21  21.66 μg/L,
39.17  25.62 μg/L, and 26.52  17.05 μg/L, respectively. The
mean  SD values of OC were 27.81  28.85 ng/mL,
37.48  37.88 ng/mL, and 35.18  38.63 ng/mL, respectively.
The distance walked in the 6MWT increased after the start of
burosumab administration (Table 2). The mean  SD distance
walked in the 6MWT was 295.8  96.0 m at baseline,
329.2  115.0 m (mean change: 33.0 m) at week 24, and
353.7  115.8 m (mean change: 57.5 m, p < 0.05) at week 48.
No notable changes were observed in the BPI throughout the
study period (Table 2), with the exception of the worst pain score
(question 3), which decreased: mean  SD scores were
4.4  2.6 at baseline, 3.0  2.7 at week 24, 2.9  2.9 at week
48, and 3.4  2.5 at week 96.
Exploratory endpoints
At baseline, a total of 143 active fractures and 21 active pseudo-
fractures were observed by whole-body bone scintigraphy. At
week 48, the numbers of “healed” fractures and pseudofractures
were 21/143 (14.7%) and 3/21 (14.3%), respectively, and the
numbers of “partially healed” fractures and pseudofractures
were 23/143 (16.1%) and 5/21 (23.8%), respectively (Fig. 4A).
The numbers for “healed” at week 96 were 43/143 (30.1%) and
7/21 (33.3%) and those for “partially healed” were 27/143
(18.9%) and 10/21 (47.6%), respectively. Neither “worse” nor
“new finding” fractures or pseudofractures were reported at
week 48 or 96. An example 99mTc-labeled bone scan image is
shown in Fig. 4B. The patient, a 57-year-old male, showed almost
complete fracture healing at week 96.
DXA results over time are shown in Supplemental Fig. S3. The
bone mineral density (BMD) of the lumbar spine was noticeably
improved from baseline to week 96, as was the BMD of the total
hip, although to a lesser extent.
Safety
At the cut-off date, 12/13 (92.3%) patients reported TEAEs. Most
TEAEs were grade 1 or 2 in severity. Treatment-related TEAEs
were reported for 5 patients (38.5%); none were grade ≥3. There
were no TEAEs leading to discontinuation or death. Four patients
(30.8%) reported serious TEAEs (septic shock, infectious gastro-
enteritis, and large intestine polyp in 1 patient; large intestine
Fig 2. Serum phosphate level over time. Data are shown as mean
+ standard deviation. The lower limit of the normal range (2.5 mg/dL) is
indicated. The number of observations at each time point are shown
below the graph.
Fig 3. Pharmacodynamic parameters over time. (A) Serum
1,25-dihydroxyvitamin D, (B) TmP/GFR, and (C) alkaline phosphatase.
Data are shown as mean + standard deviation. For (A) serum
1,25-dihydroxyvitamin D, normal range according to the central labora-
tory range of 20 to 60 pg/mL is indicated. For (C) alkaline phosphatase,
normal range according to the central laboratory range of 115 to
359 U/L is indicated. The number of observations at each time point
are shown below each graph. TmP/GFR = renal tubular maximum phos-
phate reabsorption rate/glomerular filtration rate.
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polyp in 1 patient; herpes zoster in 1 patient; septic shock in
1 patient), but none were judged by the investigator to be
related to study treatment. Table 3 shows the most frequently
reported TEAEs (in ≥2 patients) and Supplemental Table S2
shows treatment-related TEAEs.
Renal function data (serum creatinine and eGFR) are reported
in Supplemental Fig. S4. No notable changes were observed dur-
ing the study period, indicating that burosumab treatment was
not associated with alterations of renal function. Values related
to calcium homeostasis (serum corrected calcium, 24-hour urine
calcium, and intact parathyroid hormone) are shown in Supple-
mental Fig. S5. No changes in any calcium-related parameters
were observed. On renal ultrasound, nephrocalcinosis was
reported (score >0) for 4 patients at baseline through to week
48, but no patient had an increase of >1 point. Nephrolithiasis






Brief pain inventory—worst pain score
Baseline 13 4.4 (2.6) —
Week 24 12 3.0 (2.7) −1.3 (1.7)
Week 48 12 2.9 (2.9) −1.3 (2.8)
Week 96 12 3.4 (2.5) −0.8 (1.5)
6-minute walk test (m)
Baseline 13 295.8 (96.0) —
Week 12 13 314.2 (107.5) 18.4 (40.5)
Week 24 12 329.2 (115.0) 33.0 (44.8)
Week 48 12 353.7 (115.8) 57.5 (42.8)
SD = standard deviation.
Fig 4. Outcomes of the 99mTC bone scan. (A) Evaluation of fractures and pseudofractures. (B) A 99mTc-labeled bone scan image of a 57-year-old male at
baseline and at week 96. For the evaluation of fractures and pseudofractures, the% value (the percentage of active fractures remaining, ie, any status other
than “healed”) was calculated as the count of each item/total count of each visit.
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was reported for 1 patient, with the first observation at week 24;
it was no longer present at week 96.
Abnormal echocardiogram findings were reported for
2 patients. Anterior-septal partial hypokinesis was reported at
baseline and week 24 for 1 patient. For the second patient,
who had chronic heart failure complications, left ventricular dys-
function, left atrial dilatation, and left ventricular mild mitral
regurgitation were reported at baseline, and left ventricular asy-
nergy and mild mitral regurgitation were reported at weeks
24 and 48.
With regard to immunogenicity, 1 patient tested positive for
anti-burosumab binding antibody at baseline, but at all other
visits these were negative for all patients; no neutralizing anti-
bodies were detected at any time. No other instances of anti-
burosumab binding antibody or neutralizing antibody were
detected at any point. Tumor images were obtained from
7 patients by magnetic resonance imaging. No events of tumor
progression were reported.
Discussion
This clinical study, conducted in Japan and the Republic of Korea,
was the first to examine the outcomes of burosumab treatment
in TIO patients. Although most of the patients had been previ-
ously treated with active vitamin D and/or inorganic phosphate,
the interim study results showed that serum phosphate levels
increased after burosumab administration. In summary, 69.2%
of patients achieved mean peak serum phosphate levels above
the LLN and 46.2% of patients achieved mean trough levels
above the LLN; the distance walked in the 6MWT increased after
the start of burosumab administration; worst pain scores
decreased; and the number of fractures and pseudofractures
was reduced. These findings suggest the efficacy of burosumab
in TIO patients who commonly have higher FGF23
concentrations(24) and elevated bone biomarker levels(25) com-
pared with XLH patients.
The only previous clinical study in TIO patients with burosu-
mabwas the phase 2 study in the US.(20) The results of the 2 stud-
ies were similar, confirming that burosumab was able to increase
levels of serum phosphate, serum 1,25(OH)2D, and TmP/GFR. In
both studies, bone biomarkers initially increased after burosu-
mab initiation but gradually decreased after week 16. In our
study, worst pain scores improved from baseline, and the dis-
tance walked in the 6MWT increased after burosumab treatment
initiation. Taken together, these data suggest burosumab has
the potential to restore normal phosphate levels and could pro-
vide clinical benefit to patients with TIO, a group for whom ade-
quate treatment is currently lacking.
Of note, in the present study, the improvement in BPI worst
pain score was not as marked as we would have expected con-
sidering the evidence of fracture healing. One of the possible
explanations for this is that during treatment with burosumab,
bone fractures and pseudofractures improved with an increase
of serum phosphate concentration, and BPI pain tended to
improve with time. However, the enrolled patients had an aver-
age age of 60.5 years and an average duration of disease of
10.0 years. Therefore, these patients were likely to have a wide
range of complications other than TIO that may have contrib-
uted to their pain. Another possible reason is that the baseline
BPI worst pain score in this study was relatively low at 4.4,
whereas in a global study targeting XLH patients,(26) the baseline
BPI worst pain score was higher at 6.7. Therefore, the relatively
low BPI worst pain scores at baseline in the patients enrolled in
the present study may have led to minor changes with burosu-
mab administration.
In the present study, the efficacy of burosumab by histomor-
phometry data could not be confirmed because the number of
cases was small. However, when evaluating individual data, of
the 3 patients with very severe osteomalacia, 1 patient showed
no changes in histomorphometry parameters or serum phos-
phate levels byweek 48. The other 2 patients showed an increase
in serum phosphate levels and slight improvement in bone
biopsy parameters.
Burosumab administration was initiated at a low dose (0.3 mg/
kg) in this study, and titrated intra-individually according to the
serum phosphate level. Themean dose after week 52 was approx-
imately 1.0 mg/kg. However, the optimal dose of burosumab in
TIO varied widely, and approximately half of TIO patients required
higher doses compared with XLH patients.(15,16)
The treatment of choice for patients with TIO is surgical re-
section of the causative tumor.(4) Surgical resection may still be
more effective when compared with burosumab treatment,
although conducting comparative analyses would be difficult
because of the small patient population. However, in patients
with unresectable tumors or those in whom causative tumors
are not found, currently available treatments have had limited
efficacy in healing the osteomalacia, reducing symptoms, and
maintaining serum phosphate, parathyroid hormone, and alka-
line phosphatase levels within the normal range;(4) thus, burosu-
mab may satisfy the unmet need for this population. All of the
patients enrolled in this study had previously used conventional
therapy (oral inorganic phosphate and/or active vitamin D3).
From this, given that a proportion of fractures and pseudofrac-
tures were found to have healed or improved after the initiation
of burosumab, we can speculate that burosumab may be more
effective than current treatment, although it must be remem-
bered that direct comparisons were not conducted in this study.
Table 3. Summary of Treatment-Emergent Adverse Events
(Occurring in n ≥2 Patients)
TEAE, preferred term Safety analysis set N = 13
Any TEAE 12 (92.3)











Herpes zoster 2 (15.4)




Septic shock 2 (15.4)
Tooth fracture 2 (15.4)
Data are shown as n (%).
TEAE = treatment-emergent adverse event.
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Burosumab was generally well tolerated, with no treatment-
related TEAEs of grade ≥3 and no severe AEs. Similarly, in the
US study in patients with TIO, treatment-related AEs were mild
in severity.(20) Two patients discontinued during our study, 1
because of disease progression and 1 who withdrew consent.
No clinically relevant changes in serum calcium, urinary calcium,
or intact parathyroid hormone were observed throughout this
study, and no clinically significant evidence of hyperphosphate-
mia or ectopic renal calcification by ultrasound was observed.
The following study limitations must be considered when
evaluating the data. First, this study was a single-arm, open-label
study in Japanese and Korean TIO patients and did not include a
comparative control group. Second, only 13 patients were
enrolled in this study and received burosumab. However, the
evaluation of fracture/pseudofracture and bone biopsy samples
was performed by an independent central reviewer and was
considered reliable, increasing the robustness of the study.
In this first report of burosumab to treat patients with TIO,
these interim study results indicate that burosumab exhibits an
acceptable safety profile and has the potential to provide clinical
benefit for patients with unresectable tumors. The full results of
the study will be the subject of a future article and are eagerly
anticipated.
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